|
 The company said its lowest tested dose of 0.6 mg of the nasal drug
Tefina showed a statistically significant increase, compared with a
placebo, in the number of orgasms in pre- and post-menopausal
patients with female orgasmic disorder.
The study, which tested three doses of the drug, enrolled 253
patients who were treated over 84 days in a home setting, Trimel
said.
The company did not report the findings from the other two tested
doses of Tefina, a low-dose gel formulation of testosterone.
Trimel reported in February 2012 that the drug improved the
occurrence of orgasms in a smaller mid-stage study conducted in a
hospital setting.
Trimel said on Wednesday that the drug improved sexual functioning
and satisfaction, and reduced distress. It was also well-tolerated,
with no serious adverse events reported.
Female orgasmic disorder, also known as anorgasmia, is characterized
by a delay, absence or reduced intensity of orgasms, leading to
distress.
There is no approved treatment for the condition, but patients are
often given hormone tablets and patches.
[to top of second column] |
Trimel's stock closed at 70 Canadian cents on Tuesday on the Toronto
Stock Exchange.
(Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey
and Savio D'Souza)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
